SFCM
ACRS icon

Seven Fleet Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

Seven Fleet Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-107,419
Closed -$323K – 116
2025
Q4 		$323K Buy
+107,419
New +$271K 0.22% 56

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Seven Fleet Capital Management's ACRS Position: Q1 2026 in Review

Seven Fleet Capital Management sold out of Aclaris Therapeutics (ACRS) in Q1 2026, closing a stake of 107,419 shares — an estimated $323K sold.

Seven Fleet Capital Management first reported a position in ACRS in Q4 2025 and held it in 1 quarter. The position peaked at $323K in Q4 2025. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Seven Fleet Capital Management reported no remaining Aclaris Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Seven Fleet Capital Management sold 107,419 Aclaris Therapeutics shares in Q1 2026, an estimated $323K.
  • Seven Fleet Capital Management first reported a position in Aclaris Therapeutics in Q4 2025 and held it in 1 quarter.
  • Seven Fleet Capital Management's Aclaris Therapeutics position peaked at $323K in Q4 2025.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Seven Fleet Capital Management's 13F filing for Q1 2026, filed 15 May 2026.